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In all, 146 premenopausal women with early stage breast cancer were treated with adjuvant chemotherapy. In addition, 5-year
tamoxifen treatment was started after chemotherapy to those 112 patients with hormone-receptor-positive tumours while those
with hormone-receptor-negative tumours received no further therapy. The serum lipid levels were followed in both groups. The
levels of serum total and low-density lipoprotein (LDL) cholesterol increased significantly after chemotherapy only in patients who
developed ovarian dysfunction. Total cholesterol increased þ9.5% and LDL cholesterol þ16.6% in patients who developed
amenorrhoea (Po0.00001 and 0.00001, respectively). The cholesterol levels did not change in patients who preserved regular
menstruation after chemotherapy. After 6 months of tamoxifen therapy, the total cholesterol decreased  9.7% and the LDL
cholesterol  16.7% from levels after the chemotherapy, while the cholesterol concentrations remained at increased levels in the
control group (P¼0.001 and Po0.0001, respectively). The high-density lipoprotein cholesterol levels did not change significantly in
either tamoxifen or control group. The effects of tamoxifen treatment on serum lipids after chemotherapy have not been studied
before. Our current study suggests that adjuvant tamoxifen therapy reverses the adverse effects of chemotherapy-induced ovarian
failure on total and LDL cholesterol and even lowers their serum levels below the baseline.
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Adjuvant chemotherapy significantly improves survival of pre-
menopausal and perimenopausal breast cancer patients (Early
Breast Cancer Trialists‘ Collaborative Group, 1998a). In a majority
of these patients, however, adjuvant chemotherapy causes ovarian
failure. The incidence of adjuvant chemotherapy induced amenor-
rhoea varies from 26 to 89% depending on the drug combination
used (Del Mastro et al, 1997). Most data are available on regimens
based on cyclophosphamide, methotrexate and fluorouracil (CMF)
and the average rate of CMF-induced ovarian failure is 68% (Bines
et al, 1996). Women most prone to develop ovarian failure are
those in their 40s, while women under 40 years of age have better
preservation of menstruation after combination chemotherapy
(Koyama et al, 1977; Bonadonna et al, 1985; Ludwig Breast Cancer
Study Group, 1985; Padmanabhan et al, 1987; Richards et al, 1990;
Bianco et al, 1991; Bines et al, 1996).
The effects of chemotherapy on serum lipids in premenopausal
women with breast cancer have been somewhat conflicting in the
few studies available on subject. The levels of low-density
lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol
decreased and total cholesterol increased only slightly after
chemotherapy in one study (Rzymowska, 1999), while in another
study HDL cholesterol levels increased and total cholesterol levels
decreased (Subramaniam et al, 1991). We have previously shown
that the changes in serum lipids after adjuvant chemotherapy
correlate to the changes in menstruation: total cholesterol, LDL
and HDL cholesterol levels increased significantly only in patients
with chemotherapy-induced ovarian dysfunction, while patients
who preserved menstruation had no changes in these serum lipid
levels (Saarto et al, 1996a). The effects of chemotherapy on serum
triglyceride levels have varied across the studies (Subramaniam
et al, 1991; Saarto et al, 1996a; Rzymowska, 1999).
Both natural and surgical menopause cause changes in serum
lipids that are explained by the deficiency of oestrogens: serum
total and LDL cholesterol and triglyceride levels increase and HDL
cholesterol levels decrease (Matthews et al, 1989; Newnhamn 1993;
Stevenson et al, 1993; Schaefer et al, 1994; Fukami et al, 1995).
These adverse effects of menopause on serum lipids are reversed
by hormone replacement therapy (Rijpkema et al, 1990; Nabulsi
et al, 1993; Newnhamn, 1993; Writing Group for the PEPI Trial,
1995; Pripp et al, 1999). A few observational trials suggested a
protective effect against coronary heart disease (CHD) among
users of oestrogen or combined oestrogen and progestin (Stampfer
and Colditz, 1991; Grady et al, 1992). However, two more recent
large randomised trials have failed to show any cardioprotection
among hormone replacement therapy users (Hulley et al, 1998;
Manson et al 2003). The effects of tamoxifen on serum lipids have
been extensively studied. Uniformly, the levels of total cholesterol
and LDL cholesterol decrease significantly during tamoxifen
treatment, but the effects on HDL cholesterol and triglycerides
have varied (Love et al, 1990; Grey et al, 1995; Saarto et al, 1996b;
Decensi et al, 1998). Two retrospective, randomised trials
suggested that tamoxifen might have a cardioprotective effect in
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lpostmenopausal women (McDonald and Stewart, 1991; Rutqvist
and Mattsson, 1993). However, a large placebo-controlled rando-
mised study failed to show any effects of tamoxifen on
cardiovascular risk (Fisher et al, 1998).
Adjuvant tamoxifen treatment given after chemotherapy extends
disease-free and overall survival for oestrogen receptor-positive
breast cancer (Early Breast Cancer Trialists‘ Collaborative Group,
1992, 1998b). So far no studies are available on the effects of
chemotherapy followed by tamoxifen on serum lipid levels. The
aim of this study was to investigate whether tamoxifen treatment
after chemotherapy could reverse the adverse effects of che-
motherapy on serum lipid levels in premenopausal women with
breast cancer.
MATERIALS AND METHODS
Patients
The study population consists of 159 premenopausal newly
diagnosed breast cancer patients with operable T1-3 N0-2 M0
breast cancer, treated between January 1998 and May 2001 at
Helsinki University Hospital, Department of Oncology. Exclusion
criteria were the following: (1) Karnofsky performance index o70,
(2) hysterectomy or bilateral ovariectomy, (3) pregnancy or
lactation, (4) age 455 years, (5) untreated hypothyreosis or
hyperthyreosis and (6) other malignancies. Premenopausal status
was defined as ongoing menstruation during the last 6 months.
Four patients used a levonorgestrel-releasing intrauterine system
(LNG IUS) as a contraceptive device at entry and therefore had
sparse menstruation; baseline levels of follicle-stimulating hor-
mone (FSH) were within premenopausal range (4.2–18.9IUl
 1)
also in these patients.
Of the 159 patients at entry, 13 patients were excluded.
Four patients developed distant metastases before 1 year of
follow-up, four patients discontinued follow-up, three patients
had medication affecting lipid metabolism, one patient had
missing baseline lipid values and one patient was diagnosed with
untreated hypothyreosis. Overall, 146 patients were eligible for
analyses.
All patients underwent surgery with axillary evacuation and total
mastectomy or breast-conserving resection. Postoperative radio-
therapy was given to those treated with breast-conserving surgery
and to those diagnosed with axillary lymph node metastases. All
patients were treated with adjuvant chemotherapy. The standard
adjuvant chemotherapy regimen at Helsinki University Hospital
was changed during the study period. Consequently, 73 patients
received six cycles of cyclophosphamide (600mgm
 2), metho-
trexate (40mgm
 2) and 5-fluorouracil (600mgm
 2) intravenously
on day 1 with 3 weeks’ intervals and one cycle of cyclopho-
sphamide during the radiotherapy (CMF). In total, 72 patients
received six to nine cycles of cyclophosphamide (600mgm
 2),
epirubicin (60mgm
 2) and 5-fluorouracil (600mgm
 2) intrave-
nously similarly with 3 weeks’ intervals (CEF) while one patient
received four cycles of cyclophosphamide (600mgm
 2) and
adriamycin (60mgm
 2). All patients were treated with a
prophylactic antiemetic regimen typically consisting of a serotonin
(HT3) receptor antagonist (tropisetron or granisetron), metoclo-
pramide and dexamethasone. After the chemotherapy, adjuvant 5-
year tamoxifen was recommended to hormone-receptor-positive
patients.
In addition, the first 48 patients were randomly allocated to
receive intermittent intravenous clodronate treatment or no
further therapy. A measure of 1500mg of clodronate was given
in saline over 3h before each chemotherapy infusion for seven
consecutive cycles. Randomisation was later interrupted due to
conflicting results of adjuvant clodronate trials (Diel et al, 1998;
Saarto et al, 2001; Powles et al, 2002).
Methods
Informed consent was obtained from all participants. The study
was approved by the Local Ethical Committee, at the Department
of Oncology, at the Helsinki University Hospital. Staging
investigations for breast cancer included clinical investigation,
liver ultrasound and bone scintigraphy. Basic laboratory tests
before randomisation included a complete blood count and
sedimentation rate, liver enzymes (transaminase, alkaline phos-
phatase, 5-nucleotidase), serum creatinine, albumin, calcium and
kalium. Patients were interviewed regarding menopausal status,
medications and other diseases before randomisation and at 6 and
12 months. Permanent amenorrhoea was defined as absent
menstruation for at least 6 months. At 12 months, the patients
were divided into three groups with respect to menstrual function
after chemotherapy (regular menstruation, irregular menstruation
and amenorrhoea). The following measurements were analysed
from the fasting blood samples before the initiation of therapy and
at 3, 6, 9 and 12 months: serum concentrations of total cholesterol,
LDL cholesterol, HDL cholesterol, triglycerides, serum FSH,
luteinizing hormone (LH) and oestradiol.
The serum cholesterol level was determined with an enzymatic
colorimetric CHOD-PAP method and the triglyceride level with an
enzymatic colorimetric GPO-PAP method (Roche Diagnostics).
The concentration of HDL cholesterol was measured by an
enzymatic HDL-C plus second-generation method (Roche Diag-
nostics). The equipment used to measure serum cholesterol, HDL-
cholesterol and triglyceride levels was Hitachi 917 or Modular
analysator (Hitachi Ltd, Tokyo, Japan). LDL cholesterol was
calculated according to Friedewald equation (LDL cholesterol¼
cholesterol   HDL cholesterol   Trigly/2.2) (Friedewald et al,
1972).
Statistical methods
The Wilcoxon matched pair test was used to compare lipid and
hormonal changes from baseline to 6 months within each
menstrual group (regular menses, irregular menses and amenor-
rhoea). The Wilcoxon matched pair test was also used to test lipid
changes from 6 to 9 months and from 6 to 12 months within the
tamoxifen and control groups. The differences between the
menstrual groups were tested by a repeated measures ANOVA
model using the programs Statistical Package for the Social Science
(SPSS) for Macintosh. Similarly, the effects of tamoxifen and
clodronate treatment on changes in serum lipids were tested by
repeated measures ANOVA. The correlations between the changes
in serum lipids and weight were assessed by Spearman’s rank-
order correlation coefficient. Other comparisons were made using
the Mann–Whitney test. Owing to multiple comparisons, the
significance level was set at 0.01.
RESULTS
Responses of serum lipids to chemotherapy-induced
ovarian dysfunction (from baseline to 6 months)
Chemotherapy caused amenorrhoea in the majority of the patients.
During 1 year follow-up, 78 patients of 146 (53%) had developed
permanent amenorrhoea (absence of menstruation for at least 6
months) and 47 (32%) had irregular menstruation, while only 21
patients (14%) had regular menstruation. The mean age of the
patients at the start of the chemotherapy was 47 years for those
who developed amenorrhoea, 41 years for those with irregular
menstruation and 36 years for those who preserved regular
menstruation, respectively.
The gonadotropin FSH and LH changes during the chemo-
therapy period correlated with the changes observed in menstrual
cycle. In patients who developed amenorrhoea, the median value of
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 1 (Po0.00001). The median FSH
value rose from 5.30 to 47.90 IUl
 1 (Po0.00001) in patients with
irregular menstruation and from 5.10 to 19.60IUl
 1 (P¼0.0001)
in those who preserved regular menstruation. Similarly, the
median LH values rose significantly during the chemotherapy in
each menstrual group (Table 1).
Changes in total and LDL cholesterol during the chemotherapy
correlated significantly with menstrual function. Only those
patients who developed either amenorrhoea or irregular menstrua-
tion had marked elevations in serum total and LDL cholesterol,
while no significant changes occurred in those who preserved
regular menstruation.
In patients who developed amenorrhoea, the total cholesterol
increased by þ9.5% and the LDL cholesterol by þ16.6%
(Po0.00001 and 0.00001, respectively). The LDL/HDL ratio
increased by 21.7% (Po0.00001) and the total cholesterol/HDL
ratio by þ13.3% (Po0.00001).
The total cholesterol increased by þ7.3% and LDL cholesterol
by þ11.8% in patients with irregular menstruation (P¼0.003 and
0.017, respectively). The LDL/HDL ratio increased by þ14.7%
(P¼0.02) and the cholesterol/HDL ratio þ9.4% (P¼0.005).
In patients who preserved regular menstruation, the total
cholesterol increased only þ2.4% and the LDL cholesterol
þ3.0% (P¼0.52 and 0.57, respectively). Accordingly, LDL/HDL
cholesterol and cholesterol/HDL cholesterol ratios remained un-
changed (Table 1).
The differences in the changes of serum total and LDL
cholesterol were insignificant between patients with amenorrhoea
and irregular menstruation (P¼0.61 and 0.22, respectively), but
the differences in the changes of serum total and LDL cholesterol
between patients with regular menses and irregular or absent
menstruation (amenorrhoea) were more marked (P¼0.04 and
0.008). Similarly, the differences in the changes of LDL/HDL ratios
and total cholesterol/HDL ratios were insignificant between
patients with amenorrhoea and irregular menstruation (P¼0.50
and 0.84), but the differences in the changes of LDL/HDL ratios
were significant (P¼0.006) and of total cholesterol/HDL ratios
nearly significant (P¼0.02) between patients with regular menses
and irregular or absent menstruation (amenorrhoea). Serum
triglyceride levels increased and HDL cholesterol levels slightly
decreased regardless of menstrual function and the differences
between the groups were statistically insignificant (Table 1).
The mean weight gain during the chemotherapy was 2.5kg for
those who preserved regular menstruation, 2.0kg for those with
irregular menstruation and 1.2kg for those with amenorrhoea. No
correlation was found between the changes in weight and serum
lipids (total cholesterol, LDL cholesterol, HDL cholesterol and
triglycerides).
Effect of adjuvant chemotherapy followed by tamoxifen on
serum lipids (from 6 to 12 months)
After the chemotherapy period at 6 months, adjuvant 5-year
tamoxifen was started to those 112 patients with hormone-
receptor-positive tumours (tamoxifen group). In all, 34 patients
with hormone-receptor-negative tumours received no further
medication (control group). The patient characteristics (age,
weight, body mass index, serum FSH, LH and oestradiol) were
well balanced in the tamoxifen and control groups as well as the
baseline values of the serum lipids (Table 2). All differences in
these pretreatment characteristics between the treatment groups
were statistically nonsignificant. Overall, 67% of the women who
continued to menstruate regularly after the chemotherapy, 77% of
the women who developed irregular menstruation and 79% of the
women who became amenorrhoeic went on to tamoxifen. The
differences in the relative proportions of the women starting
tamoxifen were insignificant between the three menstrual groups
(P¼0.29). In the control group, the changes seen in the serum
T
a
b
l
e
1
H
o
r
m
o
n
a
l
a
n
d
l
i
p
i
d
l
e
v
e
l
s
a
f
t
e
r
t
h
e
c
h
e
m
o
t
h
e
r
a
p
y
a
c
c
o
r
d
i
n
g
t
o
m
e
n
s
t
r
u
a
l
s
t
a
t
u
s
a
t
1
2
m
o
n
t
h
s
R
e
g
u
l
a
r
m
e
n
s
e
s
I
r
r
e
g
u
l
a
r
m
e
n
s
e
s
A
m
e
n
o
r
r
h
o
e
a
B
a
s
e
l
i
n
e
3
m
o
n
t
h
s
6
m
o
n
t
h
s
B
a
s
e
l
i
n
e
3
m
o
n
t
h
s
6
m
o
n
t
h
s
B
a
s
e
l
i
n
e
3
m
o
n
t
h
s
6
m
o
n
t
h
s
F
S
H
(
I
U
l
 
1
)
*
5
.
1
0
(
1
.
4
0
–
1
1
.
4
0
)
8
.
3
0
(
2
.
1
0
–
5
3
.
1
0
)
a
1
9
.
6
0
(
4
.
5
0
–
8
3
.
4
0
)
b
5
.
3
0
(
1
.
4
0
–
3
9
.
3
0
)
2
3
.
5
0
(
2
.
4
0
–
6
4
.
5
0
)
c
4
7
.
9
0
(
2
.
0
0
–
9
6
.
1
0
)
c
,
e
5
.
4
5
(
1
.
6
0
–
9
6
.
6
0
)
6
5
.
6
0
(
5
.
9
0
–
1
4
6
.
0
0
)
c
7
1
.
1
0
(
3
1
.
0
0
–
1
4
6
.
0
0
)
c
,
d
L
H
(
I
U
l
 
1
)
*
4
.
8
0
(
0
.
6
0
–
1
5
.
0
)
7
.
0
0
(
3
.
4
0
–
3
6
.
7
0
)
2
0
.
5
0
(
4
.
1
0
–
5
8
.
3
0
)
b
4
.
2
0
(
1
.
0
0
–
3
7
.
6
0
)
1
6
.
1
0
(
2
.
4
0
–
4
3
.
4
0
)
c
2
8
.
1
0
(
0
.
7
0
–
5
6
.
4
0
)
c
,
e
4
.
8
0
(
0
.
7
0
–
5
0
.
0
0
)
3
6
.
2
5
(
5
.
5
0
–
7
0
.
5
0
)
c
3
3
.
8
0
(
1
5
.
2
0
–
7
4
.
4
0
)
c
,
d
O
e
s
t
r
a
d
i
o
l
(
n
m
o
l
l
 
1
)
*
0
.
2
4
(
0
.
0
4
–
0
.
9
1
)
0
.
1
8
(
0
.
0
3
–
0
.
6
5
)
0
.
2
0
(
0
.
0
2
–
0
.
8
4
)
0
.
2
0
(
0
.
0
3
–
1
.
2
9
)
0
.
1
7
(
0
.
0
2
–
0
.
9
4
)
0
.
0
8
(
0
.
0
2
–
1
.
2
6
)
e
0
.
2
8
(
0
.
0
2
–
1
.
2
0
)
0
.
0
2
(
0
.
0
2
–
0
.
7
5
)
c
0
.
0
2
(
0
.
0
2
–
0
.
2
9
)
c
,
e
C
h
o
l
e
s
t
e
r
o
l
(
m
m
o
l
l
 
1
)
*
*
5
.
2
2
(
0
.
8
0
)
5
.
2
5
(
0
.
7
9
)
5
.
3
1
(
0
.
8
4
)
5
.
0
0
(
0
.
8
2
)
5
.
3
1
(
0
.
8
9
)
a
5
.
3
3
(
0
.
9
8
)
a
5
.
4
4
(
0
.
8
3
)
5
.
8
0
(
0
.
9
6
)
b
5
.
9
1
(
0
.
9
8
)
c
L
D
L
(
m
m
o
l
l
 
1
)
*
*
3
.
1
6
(
0
.
6
9
)
3
.
0
4
(
0
.
7
6
)
3
.
2
2
(
0
.
7
8
)
2
.
8
3
(
0
.
7
9
)
3
.
0
2
(
0
.
8
3
)
a
3
.
0
8
(
0
.
8
5
)
3
.
0
7
(
0
.
7
2
)
3
.
3
1
(
0
.
9
3
)
b
3
.
5
3
(
0
.
9
2
)
c
H
D
L
(
m
m
o
l
l
 
1
)
*
*
1
.
6
4
(
0
.
2
9
)
1
.
6
8
(
0
.
3
4
)
1
.
6
1
(
0
.
3
3
)
1
.
7
7
(
0
.
4
0
)
1
.
8
0
(
0
.
4
8
)
1
.
7
5
(
0
.
4
4
)
1
.
9
0
(
0
.
4
3
)
1
.
9
1
(
0
.
4
9
)
1
.
8
5
(
0
.
4
0
)
T
r
i
g
l
y
c
e
r
i
d
e
(
m
m
o
l
l
 
1
)
*
*
0
.
9
4
(
0
.
5
0
)
1
.
1
5
(
0
.
7
3
)
1
.
0
4
(
0
.
5
1
)
0
.
8
9
(
0
.
3
2
)
1
.
0
9
(
0
.
5
9
)
a
1
.
0
8
(
0
.
6
0
)
1
.
0
3
(
0
.
5
3
)
1
.
2
6
(
0
.
7
2
)
b
1
.
1
6
(
0
.
5
7
)
a
L
D
L
/
H
D
L
*
*
2
.
0
2
(
0
.
6
7
)
1
.
9
3
(
0
.
7
5
)
2
.
1
2
(
0
.
7
8
)
1
.
7
0
(
0
.
6
5
)
1
.
8
3
(
0
.
7
7
)
1
.
8
9
(
0
.
7
4
)
1
.
7
2
(
0
.
6
2
)
1
.
8
8
(
0
.
8
0
)
a
2
.
0
1
(
0
.
7
0
)
c
C
h
o
l
e
s
t
e
r
o
l
/
H
D
L
*
*
3
.
2
9
(
0
.
8
3
)
3
.
2
8
(
0
.
9
6
)
3
.
4
3
(
0
.
9
0
)
2
.
9
4
(
0
.
7
3
)
3
.
1
3
(
0
.
9
1
)
3
.
2
1
(
0
.
9
3
)
a
2
.
9
8
(
0
.
7
4
)
3
.
2
3
(
1
.
0
2
)
a
3
.
3
2
(
0
.
8
2
)
c
*
M
e
d
i
a
n
(
r
a
n
g
e
)
,
*
*
M
e
a
n
(
s
.
d
.
)
.
S
i
g
n
i
f
i
c
a
n
c
e
o
f
t
h
e
c
h
a
n
g
e
s
f
r
o
m
b
a
s
e
l
i
n
e
t
o
3
a
n
d
6
m
o
n
t
h
s
w
i
t
h
i
n
t
h
e
g
r
o
u
p
s
.
a
P
o
0
.
0
1
.
b
P
o
0
.
0
0
1
.
c
P
o
0
.
0
0
0
0
1
.
N
o
n
e
o
f
t
h
e
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
r
e
g
u
l
a
r
a
n
d
i
r
r
e
g
u
l
a
r
m
e
n
s
e
s
g
r
o
u
p
s
i
n
c
h
a
n
g
e
s
f
r
o
m
b
a
s
e
l
i
n
e
t
o
6
m
o
n
t
h
s
w
e
r
e
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
.
D
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
r
e
g
u
l
a
r
m
e
n
s
e
s
a
n
d
a
m
e
n
o
r
r
h
o
e
a
g
r
o
u
p
s
i
n
c
h
a
n
g
e
s
f
r
o
m
b
a
s
e
l
i
n
e
t
o
6
m
o
n
t
h
s
:
d
P
o
0
.
0
0
0
0
1
.
D
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
i
r
r
e
g
u
l
a
r
m
e
n
s
e
s
a
n
d
a
m
e
n
o
r
r
h
o
e
a
g
r
o
u
p
s
i
n
c
h
a
n
g
e
s
f
r
o
m
b
a
s
e
l
i
n
e
t
o
6
m
o
n
t
h
s
:
e
P
o
0
.
0
0
0
0
1
.
Chemotherapy, tamoxifen and serum lipids
L Vehmanen et al
478
British Journal of Cancer (2004) 91(3), 476–481 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lFSH, LH, oestradiol and lipid values from 6 to 12 months did not
differ between the three menstrual groups (regular menstruation,
irregular menstruation and amenorrhoea).
The total and LDL cholesterol and triglyceride levels increased
during the chemotherapy in all patients. After 3 and 6 months of
tamoxifen treatment, the total cholesterol decreased by  9.6 and
 9.7% from the levels after chemotherapy, while total cholesterol
remained unchanged in the control group (P¼0.001 and 0.001,
respectively). The LDL cholesterol decreased by  16.0 and  16.7%
after 3 and 6 months of tamoxifen treatment while in the control
group the LDL cholesterol did not change (Po0.0001 and 0.0001,
respectively). The changes in HDL cholesterol levels after 3 and 6
months of tamoxifen therapy were insignificant both in the
tamoxifen group and in the control group (P¼0.78 and 0.94,
respectively). The serum triglyceride remained at an increased
level in both groups (Table 2).
After 3 and 6 months of tamoxifen treatment, the LDL/HDL
ratio decreased  14.7 and  15.0% from the levels after the
chemotherapy, while the LDL/HDL ratio remained at an increased
level in the control group (P¼0.006 and 0.003, respectively). A
similar trend was observed for the total cholesterol/HDL ratio
which decreased by  8.4 and  8.6% after 3 and 6 months of
tamoxifen treatment, while the changes were marginal in the
control patients (P¼0.02 and 0.02, respectively) (Table 2).
Notably, already after 3 months of tamoxifen therapy both total
and LDL cholesterol levels had decreased even below the baseline
levels measured before the chemotherapy: total cholesterol had
decreased  4.6% and LDL cholesterol  8.3% below the baseline
levels (Po0.0001 and 0.0001, respectively) (Figure 1).
Effect of clodronate on lipid levels
Totally, 19 patients were treated with intravenous clodronate in
addition to adjuvant chemotherapy. Clodronate did not have
significant effects on serum lipids (data not shown).
DISCUSSION
In line with previous findings, adjuvant chemotherapy caused
ovarian dysfunction (amenorrhoea or irregular menstruation) in
the majority of patients in the present study. The risk of
amenorrhoea was age-related, the older the women the higher
was the risk of premature menopause after chemotherapy. As we
have reported previously (Saarto et al, 1996a), the changes in
serum total and LDL cholesterol correlated significantly with
menstrual function after chemotherapy. The total and LDL
cholesterol levels increased significantly only in patients who
developed ovarian dysfunction while no changes were seen in
patients who preserved regular menstruation. In the present study,
HDL cholesterol remained unchanged in the patients with ovarian
dysfunction while it even increased in our previous study.
Table 2 Lipid levels in the tamoxifen and control groups
Tamoxifen (n¼112) Control (n¼34)
Baseline 6 months 9 months 12 months Baseline 6 months 9 months 12 months
Cholesterol (mmoll
 1)* 5.29 (0.78) 5.60 (0.90) 5.02 (0.91)
a 5.02 (0.85)
a 5.18 (1.00) 5.75 (1.28) 5.69 (1.04)
b 5.58 (1.03)
b
LDL (mmoll
 1)* 3.02 (0.71) 3.30 (0.80) 2.73 (0.83)
a 2.72 (0.78)
a 2.97 (0.88) 3.46 (1.17) 3.41 (0.85)
c 3.32 (0.87)
c
HDL (mmoll
 1)* 1.83 (0.43) 1.78 (0.42) 1.77 (0.49) 1.77 (0.44) 1.79 (0.36) 1.80 (0.39) 1.81 (0.44) 1.79 (0.43)
Triglyceride (mmoll
 1)* 0.98 (0.47) 1.13 (0.58) 1.15 (0.69) 1.16 (0.63) 0.92 (0.46) 1.08 (0.54) 1.02 (0.50) 1.02 (0.50)
LDL/HDL* 1.76 (0.62) 1.98 (0.70) 1.67 (0.75)
a 1.66 (0.70)
a 1.74 (0.71) 2.02 (0.82) 1.98 (0.64)
b 1.97 (0.68)
b
Cholesterol/HDL* 3.02 (0.73) 3.30 (0.85) 3.01 (0.91)
a 3.00 (0.85)
a 2.99 (0.84) 3.31 (0.94) 3.26 (0.77) 3.26 (0.85)
*Mean (s.d.). Significance of the changes from 6 to 9 months and from 6 to 12 months within the tamoxifen and control groups:
aPo0.00001. Differences between the tamoxifen
and control groups in changes from 6 to 9 months and from 6 to 12 months:
bPo0.01.
cPo0.0001.
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Figure 1 Percentual changes from baseline (and 95% confidence
intervals) in serum total and LDL cholesterol in the tamoxifen (bold line)
and control (dotted line) groups (ANOVA repeated measurements).
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chemotherapy decreased the increased concentrations of total and
LDL cholesterol. Already after 3 months of tamoxifen therapy, the
total and the LDL cholesterol levels had decreased  4.6 and  8.3%
below the baseline levels before chemotherapy, while total and LDL
cholesterol remained at increased levels in the control group. The
HDL cholesterol levels did not change in either tamoxifen or
control group.
Tamoxifen treatment is associated with decreases in serum total
and LDL cholesterol. This has been true especially in postmeno-
pausal women (Love et al, 1990; Grey et al, 1995; Saarto et al,
1996b) but also to some extent in pre- and perimenopausal women
(Caleffi et al, 1988; Powles et al, 1994). The effects of tamoxifen
therapy on HDL cholesterol have varied across previous studies
and have mostly been marginal. Retrospective studies have
suggested a reduction of cardiac morbidity among tamoxifen
users (McDonald and Stewart, 1991; Rutqvist and Mattsson, 1993),
which has been related to the cholesterol-lowering effect of
antioestrogens. However, a large double-blind, randomised,
placebo-controlled NSABP Breast Cancer Prevention Trial (BCPT)
reported that prophylactic tamoxifen did not influence cardiovas-
cular risk in 13388 women (Fisher et al, 1998). When the study
population was further divided to those with high or low risk for
cardiovascular events, tamoxifen was not associated with beneficial
or adverse cardiovascular effects in either group (Reis et al, 2001).
Dyslipidaemia is an independent risk factor of CHD in both men
and women. Low-serum HDL cholesterol levels seem to be even a
stronger predictor of cardiovascular mortality than elevated LDL
cholesterol levels in postmenopausal women (Bass et al, 1993).
Cholesterol-lowering therapy with statins reduces cardiovascular
events (Scandinavian Simvastatin Survival Study Group, 1994;
Sacks et al, 1996; Long-term Intervention with Pravastatin in
Ischaemic Disease (LIPID) Study Group, 1998) and mortality rates
(Scandinavian Simvastatin Survival Study Group, 1994).
Hormone replacement therapy lowers total and LDL cholesterol
and increases HDL cholesterol concentrations. Observational
studies have found lower rates of CHD in postmenopausal women
who use oestrogen as compared to nonusers (Stampfer and
Colditz, 1991; Grady et al, 1992). However, two large intervention
trials (HERS and WHI) found no benefit of oestrogen–progestin
treatment on the risk of cardiovascular events (Hulley et al, 1998;
Manson et al, 2003). Oestrogen plus progestin did not inhibit
disease progression among women with established CHD and in
fact an early increase in the risk of CHD events was noted in the
HERS trial (Hulley et al, 1998). In the WHI trial, oestrogen plus
progestin did not confer cardiac protection and actually increased
the risk of CHD among generally healthy postmenopausal women,
especially during the first year after the initiation of hormone use
(Manson et al, 2003).
We conclude that adjuvant tamoxifen therapy reverses the
adverse effects of chemotherapy on total and LDL cholesterol and
lowers their serum levels even below the baseline. The serum HDL
cholesterol levels, however, remained unchanged after chemother-
apy followed by tamoxifen. The clinical implications of these
findings still need to be studied as many factors other than serum
cholesterol levels affect the risk of cardiovascular disease.
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